8 completed, 1 active not recruiting, 1 enrolling by invitation, 1 recruiting. 11 Phase 3, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 11 | Completed 8, Active not recruiting 1, Enrolling by invitation 1, Recruiting 1 |
| Phase 2 | 2 | Completed 2 |
Follow tenapanor: new trials by email Literature Review of tenapanor trials Research Report on tenapanor
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A 26-Wk Study to Assess Safety & Efficacy of Tenapanor for T/t of Chronic Idiopathic Constipation in Adults Tenapanor 5 mg BID, Tenapanor 25 mg BID, Tenapanor 50 mg BID - Chronic Idiopathic Constipation (CIC) | Phase 3 | Recruiting | Ardelyx | 692 | 2026-01-13 | 2026-06-04 |
| Assessing Tenapanor as a Treatment of CF-related Constipation. Tenapanor - Cystic Fibrosis, Constipation | Phase 3 | Active not recruiting | Massachusetts General Hospital | 25 | 2025-06-01 | 2026-08-21 |
| Safety Study of Tenapanor for the Treatment of Pediatric Patients (6 to Less Than 18 Years Old) With IBS-C Tenapanor - Irritable Bowel Syndrome With Constipation (IBS-C) | Phase 3 | Enrolling by invitation | Ardelyx | 150 | 2023-02-17 | 2026-06-04 |
| Study to Assess Safety and Efficacy of Tenapanor for Treatment of IBS-C in Pediatric Patients 12 to Less Than 18 Years Tenapanor 50 MG, Tenapanor 25 mg bid, Placebo - Irritable Bowel Syndrome With Constipation (IBS-C) | Phase 3 | Completed | Ardelyx | 180 | 2022-11-15 | 2026-09-22 |
| Study to Evaluate the Efficacy of Tenapanor as Adjunctive Therapy to Phosphate Binder Therapy Tenapanor, Placebo, Phosphate Binder Agents - Hyperphosphatemia | Phase 2 / Phase 3 | Completed | Ardelyx | 236 | 2019-02-28 | 2023-03-06 |
| A Phase 3 Study of Tenapanor to Treat Hyperphosphatemia in ESRD Patients on Dialysis Tenapanor, Placebo, Sevelamer Carbonate - Hyperphosphatemia | Phase 3 | Completed | Ardelyx | 1559 | 2018-01-08 | 2023-06-29 |
| A Long-Term Safety Study of Tenapanor for the Treatment of IBS-C Tenapanor - Constipation Predominant Irritable Bowel Syndrome | Phase 3 | Completed | Ardelyx | 312 | 2016-03-01 | 2020-09-09 |
| An 8-Week Study to Evaluate Tenapanor in the Treatment of Hyperphosphatemia in End-Stage Renal Disease Patients on Hemodialysis (ESRD-HD) Tenapanor, Placebo - Hyperphosphatemia | Phase 3 | Completed | Ardelyx | 219 | 2016-01-01 | 2020-08-10 |
| A 26-Week Study to Evaluate the Efficacy and Safety of Tenapanor in IBS-C Tenapanor, Placebo - Constipation Predominant Irritable Bowel Syndrome | Phase 3 | Completed | Ardelyx | 593 | 2015-12-01 | 2020-04-22 |
| A 12-Week Study With a 4-Week Randomized Withdrawal Period to Evaluate the Efficacy and Safety of Tenapanor for the Treatment of IBS-C Tenapanor, Placebo - Constipation Predominant Irritable Bowel Syndrome | Phase 3 | Completed | Ardelyx | 606 | 2015-10-01 | 2020-04-21 |
| The Efficacy of AZD1722 in Constipation Predominant Irritable Bowel Syndrome (IBS-C) AZD1722, Placebo - Constipation Predominant Irritable Bowel Syndrome | Phase 2 / Phase 3 | Completed | Ardelyx | 356 | 2013-08-01 | 2020-04-08 |
Hyperphosphatemia (3) · Constipation (1) · Cystic Fibrosis (1)
Ardelyx (10) · Massachusetts General Hospital (1)
United States (11)
David P Rosenbaum, Ph.D. (5) · David P Rosenbaum, PhD (2) · Jocelyn Tabora (2) · Brian Quach (1) · Christoher D Velez, MD (1)
PMID 33337659, PMID 37668173, PMID 38323855, PMID 41601848, PMID 37853560, PMID 31934897, PMID 33766811, PMID 35372979, PMID 40576086